Marketing outside the box

There’s ever-increasing menu of tools, technologies and tactics to choose from, but is pharma ready to innovate?
The impact of a 'hard Brexit'

In January, the prime minister, Theresa May, warned the EU that “no deal for Britain is better than a bad deal” when it comes to Brexit. Although her government is now edging away from that position, the statement raised the question of what no deal would actually mean for the pharma industry
Genetic data

Are the muddled laws and ethical questions surrounding privacy of genetic data impeding pharma research?
Empowering technology

How patient empowerment could change healthcare and pharma at the most fundamental level
Finalists for International Clinical Researcher of the Year 2017 announced

PharmaTimes Media is delighted to report that once again, clinical researchers from across the globe have engaged with the International Clinical Researcher of the Year competition.

News

View all

Priority review for BMS’ Opdivo in liver cancer

US regulators will undertake a speedy review of Bristol-Myers Squibb’s application to expand use of its immunotherapy Opdivo to include to include certain patients with liver cancer.

26th May 2017

Pfizer’s Epogen/Procrit biosimilar wins US backing

Pfizer’s biosimilar of Amgen’s epoetin alfa (Epogen/Procrit) has won backing in the US for approval across all proposed indications.

26th May 2017

UK researchers find evidence of ‘nocebo’ effect for statins

Patients report more side effects when they know they are taking a statin than when don’t, according to findings of a recent study led by researchers at Imperial College London, funded by Pfizer, and published in The Lancet.

26th May 2017

Merck buys experimental tau antibody from Teijin

Merck & Co has bought itself an exclusive global licence from Teijin Pharma to develop, manufacture and commercialise an investigational preclinical antibody candidate targeting a protein called tau.

26th May 2017

EU regulators widen approval for Zebinix

The European Medicines Agency has cleared use of Bial and Eisai’s sodium channel blocker Zebinix for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy, widening its treatment scope in the region.

25th May 2017

Magazine

View more from the latest edition

The impact of a 'hard Brexit'

In January, the prime minister, Theresa May, warned the EU that “no deal for Britain is better than a bad deal” when it comes to Brexit. Although her government is now edging away from that position, the statement raised the question of what no deal would actually mean for the pharma industry

Marketing outside the box

There’s ever-increasing menu of tools, technologies and tactics to choose from, but is pharma ready to innovate?

Genetic data

Are the muddled laws and ethical questions surrounding privacy of genetic data impeding pharma research?

Trials and tribulations

As pharma grapples the twin challenge of developing breakthrough innovations while reducing development costs, the contract research market continues to provide vital support. CRO leaders are well-positioned to spot the trends that are shaping clinical trials in 2017. Here are six of the best…